2015
Incremental direct and indirect costs of untreated vasomotor symptoms
Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause The Journal Of The North American Menopause Society 2015, 22: 260-266. PMID: 25714236, DOI: 10.1097/gme.0000000000000320.Peer-Reviewed Original ResearchConceptsHealthcare resource utilizationVasomotor symptomsOutpatient visitsIndirect costsHigher healthcare resource utilizationRetrospective matched-cohort studyIncremental indirect costsMatched-cohort studySevere vasomotor symptomsCause outpatient visitsHealth insurance claimsControl womenControl cohortLoss daysMost womenWork lossPropensity scoreWomenDirect costsVisitsCost burdenPatientsCohortSymptomsProductivity loss
2013
The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years.
Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. American Journal Of Public Health 2013, 103: 1583-8. PMID: 23865654, PMCID: PMC3780684, DOI: 10.2105/ajph.2013.301295.Peer-Reviewed Original ResearchConceptsEstrogen therapyHysterectomized womenEstrogen usePostmenopausal womenMortality tollHealth initiativesEffects of ETYounger postmenopausal womenWomen's Health InitiativeHealth care providersCause mortalityExcess mortalityCare providersMortality rateExcess deathsComparable womenWomenThousands of womenMortalityEntire populationYearsInformed discussionTherapyPopulationTrials
2005
Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST)
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal Of Obstetrics And Gynecology 2005, 192: 387-393. PMID: 15695976, DOI: 10.1016/j.ajog.2004.08.017.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationEstrogen therapyCognitive declineNormal Mini-Mental State ExaminationDouble-blind trialSecondary stroke preventionTransient ischemic attackIschemic attackPostmenopausal womenStroke preventionRecent strokeStroke trialsCerebrovascular diseaseWomen's EstrogenEstradiol-17betaState ExaminationCognitive measuresEstrogenWomenNormal functionDomain measuresLess declineTherapyStrokeRisk
2003
Raloxifene and endothelial function in healthy postmenopausal women
Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. American Journal Of Obstetrics And Gynecology 2003, 188: 304-309. PMID: 12592230, DOI: 10.1067/mob.2003.28.Peer-Reviewed Original ResearchConceptsPostmenopausal womenEndothelial functionPlacebo-controlled crossover trialEndothelial-mediated dilationLaser Doppler measuresEffects of raloxifeneFlow-mediated dilationHealthy postmenopausal womenBrachial artery diameter changesArtery diameter changesWarrants further studyBrachial arteryCardioprotective effectsCrossover trialDoppler measuresCurve ratioHyperemic stimulusRaloxifenePlaceboStimulus intensityDigital vesselsPotential mechanismsRatio of areaWomenFurther studies
2002
Androgen deficiency: menopause and estrogen-related factors
Sarrel PM. Androgen deficiency: menopause and estrogen-related factors. Fertility And Sterility 2002, 77: 63-67. PMID: 12007905, DOI: 10.1016/s0015-0282(02)02967-9.Peer-Reviewed Original ResearchConceptsHormone replacement therapyEffects of androgensPostmenopausal womenReplacement therapyEndogenous androgensPostmenopausal hormone replacement therapySex hormone-binding globulinAddition of androgensHormone-binding globulinMenopause-related symptomsAction of estrogenAcademic medical centerAndrogen bioavailabilityEstrogen replacementSymptom controlOvarian hormonesAndrogen replacementBone lossEstrogen depletionMenopausal womenNatural menopauseSexual functionMedical CenterAndrogen effectsEstradiol depletion